Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy
- PMID: 34157144
- PMCID: PMC8426861
- DOI: 10.1002/jcph.1929
Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy
Keywords: COVID-19; SARS-CoV-2; acute respiratory distress syndrome (ARDS); corticosteroid; cytokine release syndrome; dexamethasone; methylprednisolone.
Conflict of interest statement
The authors declare no conflicts of interest.
Comment on
-
Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.BMC Infect Dis. 2021 Apr 10;21(1):337. doi: 10.1186/s12879-021-06045-3. BMC Infect Dis. 2021. PMID: 33838657 Free PMC article. Clinical Trial.
References
-
- Arabi YM, Mandourah Y, Al‐Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757‐767. - PubMed
-
- Rodrigo C, Leonardi‐Bee J, Nguyen‐Van‐Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2016;3:CD010406. - PubMed
-
- Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990;323(21):1451‐1457. - PubMed
-
- Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671‐1684. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous